Rainforest Berry Destroys Tumors In Animals

A drug derived from the Blushwood plant has been found to be 70 percent effective in eradicating tumors in animal models.

AsianScientist (Oct. 15, 2014) – Scientists at QIMR Berghofer Medical Research Institute have used an experimental drug produced from the seeds of a rainforest plant to cure solid cancer tumors in pre-clinical trials. The study has been published in the journal PLoS One.

The study led by Dr. Glen Boyle at QIMR Berghofer’s Cancer Drug Mechanisms group found that a single injection of the drug EBC-46 led to rapid breakdown of tumors in a range of human tumor models. Boyle says the findings of the pre-clinical trials suggest the drug could be effective in human patients.

“We were able to achieve very strong results injecting EBC-46 directly into melanoma models, as well as cancers of the head, neck and colon,” Boyle said. “In most cases the single injection treatment caused the loss of viability of cancer cells within four hours, and ultimately destroyed the tumors.”

Boyle says EBC-46 works in part by triggering a cellular response which effectively cuts off the blood supply to the tumor.

“In more than 70 percent of pre-clinical cases, the response and cure was long-term and enduring, with very little relapse over a period of 12 months.”

EBC-46 is a compound extracted from the fruit of the Blushwood tree which is found in north Queensland rainforests. It was discovered by the Queensland biotechnology company EcoBiotics. The drug is being developed as a human and veterinary pharmaceutical through EcoBiotics’ subsidiary company QBiotics.

The experimental drug has been used by practicing veterinarians to successfully destroy or shrink tumors in pets—including dogs, cats and horses. QBiotics is currently undertaking formal veterinary clinical trials with EBC-46 in Australia and the USA. A final regulatory approval is still required for a human Phase I clinical trial.

Boyle says QIMR Berghofer is keen to pursue further research to determine if EBC-46 could be made more effective.

“We must stress at this point that EBC-46 will only be trialed in the short-term for tumors which can be accessed by direct injection or topical application,” Boyle said. “There is no evidence to suggest EBC-46 would be effective against metastatic cancers.”

The article can be found at: Boyle et al. (2014) Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models.

——-

Source: QIMR Berghofer Medical Research Institute.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist